Tommy Fornander
Overview
Explore the profile of Tommy Fornander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johansson A, Dar H, Nordenskjold A, Perez-Tenorio G, Tobin N, Yau C, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39656627
Background: Estrogen receptor-positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal patients have a higher risk. Randomized studies with long-term follow-up are essential to understand...
2.
Sandstrom J, Bomanson J, Perez-Tenorio G, Jonsson C, Nordenskjold B, Fornander T, et al.
NPJ Breast Cancer
. 2024 Sep;
10(1):78.
PMID: 39242600
GATA binding protein 3 (GATA3) is essential for normal development of the mammary gland and associated with ER-positive breast cancer. Loss of GATA3 has been associated with epithelial-mesenchymal transition (EMT)...
3.
Matikas A, Mobus V, Greil R, Andersson A, Steger G, Untch M, et al.
J Clin Oncol
. 2024 Jul;
42(26):3077-3082.
PMID: 39018515
JCO .Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies...
4.
Fohlin H, Nordenskjold A, Rosell J, Ferno M, Fornander T, Ryden L, et al.
Acta Oncol
. 2024 Jul;
63:535-541.
PMID: 38967128
Background: Hormone receptor positivity predicts benefit from endocrine therapy but the knowledge about the long-term survival of patients with different tumor receptor levels is limited. In this study, we describe...
5.
Nordenskjold A, Fohlin H, Rosell J, Bengtsson N, Fornander T, Hatschek T, et al.
Breast
. 2023 Jul;
71:63-68.
PMID: 37517154
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material And Methods: We studied 30 years...
6.
Wengstrom Y, Fornander T, Lindstrom L
JAMA Oncol
. 2023 Jul;
9(9):1199-1201.
PMID: 37498581
No abstract available.
7.
Pousette J, Johansson A, Jonsson C, Fornander T, Lindstrom L, Olsson H, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230767
The clinical impact of tumor-infiltrating lymphocytes (TILs) is less known for breast cancer patients with the estrogen receptor-positive (ER+)/human epidermal growth factor receptor-negative (HER−) subtype. Here, we explored the prognostic...
8.
Johansson A, Dar H, J van t Veer L, Tobin N, Perez-Tenorio G, Nordenskjold A, et al.
J Clin Oncol
. 2022 Jul;
40(35):4071-4082.
PMID: 35862873
Purpose: To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. Methods: Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to...
9.
Johansson A, Yu N, Iftimi A, Tobin N, van t Veer L, Nordenskjold B, et al.
Int J Cancer
. 2022 Feb;
150(12):2072-2082.
PMID: 35179782
The metastatic potential of estrogen receptor (ER)-positive breast cancers is heterogeneous and distant recurrences occur months to decades after primary diagnosis. We have previously shown that patients with tumors classified...
10.
Dar H, Johansson A, Nordenskjold A, Iftimi A, Yau C, Perez-Tenorio G, et al.
JAMA Netw Open
. 2021 Jun;
4(6):e2114904.
PMID: 34190995
Importance: Clinically used breast cancer markers, such as tumor size, tumor grade, progesterone receptor (PR) status, and Ki-67 status, are known to be associated with short-term survival, but the association...